A multicenter Phase II study of Epirubicin (E) with low-dose Herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary results

被引：0
|
作者：
De Tursi, M.
Carella, C.
Ricevuto, E.
Marchetti, P.
Gennari, A.
Orlandini, C.
Frassoldati, A.
Conte, P.
Iacobelli, S.
机构：
[1] Univ G dAnnunzio, Dept Oncol & Neurosci, Chieti, Italy
[2] Univ Aquila, Dept Oncol, I-67100 Laquila, Italy
[3] Univ Pisa, Dept Oncol, I-56100 Pisa, Italy
[4] Univ Modena, Dept Oncol, I-41100 Modena, Italy
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：116 / 116
页数：1
相关论文
共 50 条
  • [21] Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan
    Tokudome, Nahomi
    Ito, Yoshinori
    Hatake, Kiyohiko
    Toi, Masakazu
    Sano, Muneaki
    Iwata, Hiroji
    Sato, Yasuyuki
    Saeki, Toshiaki
    Aogi, Kenjiro
    Takashima, Shigemitsu
    ANTI-CANCER DRUGS, 2008, 19 (07) : 753 - 759
  • [22] Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first line treatment of metastatic breast cancer: Results of a multicenter phase II study
    Riccardi, A
    Brugnatelli, S
    Danova, M
    Giordano, M
    Pugliese, P
    Luchena, G
    Grasso, D
    Trotti, G
    Berte, R
    Pansini, G
    Tinelli, C
    TUMORI, 2006, 92 (01) : 6 - 12
  • [23] Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results
    Michalaki, Vasiliki
    Gennatas, Spyridon
    Gennatas, Konstantine
    ANTI-CANCER DRUGS, 2009, 20 (03) : 204 - 207
  • [24] Randomized phase II study of docetaxel vs. epirubicin/cyclophosphamide to optimize first-line therapy of metastatic breast cancer (MBC): preliminary results of the TIPP study.
    Wasemann, C
    Di Liberto, A
    Ertan, K
    Schmidt, W
    Friedrich, M
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S89 - S89
  • [25] Low-dose capecitabine monotherapy in HER-2 negative metastatic breast cancer: a retrospective study.
    Ambros, T.
    Zeichner, S. B.
    Zaravinos, J.
    Montero, A. J.
    Ahn, E.
    Mani, A.
    Kronish, L.
    Mahtani, R. L.
    Vogel, C. L.
    CANCER RESEARCH, 2012, 72
  • [26] Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)
    Datko, Farrah Mikhail
    D'Andrea, Gabriella
    Dickler, Maura N.
    Theodoulou, Maria
    Goldfarb, Shari Beth
    Lake, Diana
    Fornier, Monica Nancy
    Modi, Shanu
    Sklarin, Nancy T.
    Comen, Elizabeth Anne
    Fasano, Julie
    Gajria, Devika
    Drullinsky, Pamela
    Murphy, Conleth G.
    Syldor, Angemael
    Patil, Sujata
    Liu, Jennifer
    Chandarlapaty, Sarat
    Hudis, Clifford
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [27] Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).
    Datko, Farrah Mikhail
    D'Andrea, Gabriella
    Dickler, Maura N.
    Goldfarb, Shari Beth
    Theodoulou, Maria
    Lake, Diana
    Fornier, Monica Nancy
    Modi, Shanu
    Fasano, Julie
    Comen, Elizabeth Anne
    Gajria, Devika
    Moynahan, Mary Ellen
    Traina, Tiffany A.
    Chen, Melanie
    Hamilton, Nicola
    Patil, Sujata
    Chandarlapaty, Sarat
    Hudis, Clifford
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer
    Tryfonidis, K.
    Boukovinas, I.
    Xenidis, N.
    Christophyllakis, C.
    Papakotoulas, P.
    Politaki, E.
    Malamos, N.
    Polyzos, A.
    Kakolyris, S.
    Georgoulias, V.
    Mavroudis, D.
    BREAST, 2013, 22 (06): : 1171 - 1177
  • [29] Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer
    Mansour, Maged
    Mourad, Cynthia
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (02) : 429 - 435
  • [30] Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer
    Maged Mansour
    Cynthia Mourad
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 429 - 435
12345